These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 30049957

  • 21. Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
    Sereni MI, Baldelli E, Gambara G, Ravaggi A, Hodge KA, Alberts DS, Guillen-Rodriguez JM, Dong T, Memo M, Odicino F, Angioli R, Liotta LA, Pecorelli SL, Petricoin EF, Pierobon M.
    Br J Cancer; 2017 Aug 08; 117(4):494-502. PubMed ID: 28664915
    [Abstract] [Full Text] [Related]

  • 22. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH, Park SH, Do KH, Kim J, Choi KU, Moon Y.
    Oncotarget; 2016 Nov 01; 7(44):72148-72166. PubMed ID: 27708225
    [Abstract] [Full Text] [Related]

  • 23. Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells.
    Gupta N, Xu Z, El-Sehemy A, Steed H, Fu Y.
    Gynecol Oncol; 2013 Jul 01; 130(1):200-6. PubMed ID: 23542683
    [Abstract] [Full Text] [Related]

  • 24. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
    Bonneau C, Rouzier R, Geyl C, Cortez A, Castela M, Lis R, Daraï E, Touboul C.
    Gynecol Oncol; 2015 Jan 01; 136(1):112-20. PubMed ID: 25449309
    [Abstract] [Full Text] [Related]

  • 25. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
    Kritsch D, Hoffmann F, Steinbach D, Jansen L, Mary Photini S, Gajda M, Mosig AS, Sonnemann J, Peters S, Melnikova M, Thomale J, Dürst M, Runnebaum IB, Häfner N.
    Int J Cancer; 2017 Oct 15; 141(8):1600-1614. PubMed ID: 28670762
    [Abstract] [Full Text] [Related]

  • 26. C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin.
    Gao Z, Xu X, McClane B, Zeng Q, Litkouhi B, Welch WR, Berkowitz RS, Mok SC, Garner EI.
    Clin Cancer Res; 2011 Mar 01; 17(5):1065-74. PubMed ID: 21123456
    [Abstract] [Full Text] [Related]

  • 27. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
    Lin M, Xia B, Qin L, Chen H, Lou G.
    DNA Cell Biol; 2018 May 01; 37(5):491-500. PubMed ID: 29485916
    [Abstract] [Full Text] [Related]

  • 28. Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells.
    Moraya AI, Ali JL, Samadder P, Liang L, Morrison LC, Werbowetski-Ogilvie TE, Ogunsina M, Schweizer F, Arthur G, Nachtigal MW.
    J Exp Clin Cancer Res; 2017 May 12; 36(1):67. PubMed ID: 28499442
    [Abstract] [Full Text] [Related]

  • 29. Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase.
    Park MJ, Park IC, Hur JH, Kim MS, Lee HC, Woo SH, Lee KH, Rhee CH, Hong SI, Lee SH.
    J Neurosurg; 2002 Jul 12; 97(1):112-8. PubMed ID: 12134900
    [Abstract] [Full Text] [Related]

  • 30. SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes.
    Henklova P, Vrzal R, Papouskova B, Bednar P, Jancova P, Anzenbacherova E, Ulrichova J, Maurel P, Pavek P, Dvorak Z.
    Eur J Pharmacol; 2008 Sep 28; 593(1-3):16-23. PubMed ID: 18655782
    [Abstract] [Full Text] [Related]

  • 31. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.
    Scalici JM, Harrer C, Allen A, Jazaeri A, Atkins KA, McLachlan KR, Slack-Davis JK.
    Gynecol Oncol; 2014 Feb 28; 132(2):455-61. PubMed ID: 24378876
    [Abstract] [Full Text] [Related]

  • 32. CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway.
    Yasui H, Kajiyama H, Tamauchi S, Suzuki S, Peng Y, Yoshikawa N, Sugiyama M, Nakamura K, Kikkawa F.
    Clin Exp Metastasis; 2020 Feb 28; 37(1):145-158. PubMed ID: 31541326
    [Abstract] [Full Text] [Related]

  • 33. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X, Shen H, Yin X, Long L, Chen X, Feng F, Liu Y, Zhao P, Xu Y, Li M, Xu W, Li Y.
    Oncotarget; 2017 Jun 13; 8(24):39154-39166. PubMed ID: 28388577
    [Abstract] [Full Text] [Related]

  • 34. Epigallocatechin‑3‑gallate inhibits the proliferation and migration of human ovarian carcinoma cells by modulating p38 kinase and matrix metalloproteinase‑2.
    Wang F, Chang Z, Fan Q, Wang L.
    Mol Med Rep; 2014 Mar 13; 9(3):1085-9. PubMed ID: 24452912
    [Abstract] [Full Text] [Related]

  • 35. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.
    Lu H, Liu Y, Wang D, Wang L, Zhou H, Xu G, Xie L, Wu M, Lin Z, Yu Y, Li G.
    Tumour Biol; 2016 Aug 13; 37(8):11469-77. PubMed ID: 27012551
    [Abstract] [Full Text] [Related]

  • 36. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    Whicker ME, Lin ZP, Hanna R, Sartorelli AC, Ratner ES.
    BMC Cancer; 2016 Jul 27; 16():550. PubMed ID: 27465688
    [Abstract] [Full Text] [Related]

  • 37. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I, Ladislau-Magescky T, Tessarollo NG, Dos Santos DZ, Gimba ERP, Sternberg C, Silva IV, Rangel LBA.
    Pharmacol Rep; 2018 Jun 27; 70(3):409-417. PubMed ID: 29627688
    [Abstract] [Full Text] [Related]

  • 38. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling.
    Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE, Dugan CM, Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM, Burow ME.
    Int J Oncol; 2004 Jun 27; 24(6):1473-80. PubMed ID: 15138590
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.